首页 | 本学科首页   官方微博 | 高级检索  
     

肌肉减少症对接受TACE治疗原发性肝癌患者生存期的影响
引用本文:向谦,陈丽,付丹,徐庆,叶斌,陈霞. 肌肉减少症对接受TACE治疗原发性肝癌患者生存期的影响[J]. 现代消化及介入诊疗, 2021, 0(2): 202-207
作者姓名:向谦  陈丽  付丹  徐庆  叶斌  陈霞
作者单位:成都市第六人民医院消化内科;成都市第六人民医院放射科;成都市第六人民医院肿瘤科
摘    要:目的 肌肉减少症(Src)对经导管动脉化疗栓塞术(TACE)预后的影响尚不十分明确,拟评估术前Src与TACE治疗后生存期的影响.方法 回顾性分析2014年1月至2018年1月在成都市第六人民医院初次诊断和接受首次TACE治疗的155例原发性肝癌(HCC)患者的资料,依据纳入排除标准筛选其中98例纳入分析.依据术前CT...

关 键 词:肌肉减少症  经导管动脉化疗栓塞术  原发性肝癌  预后

Sarcopenia as a Predictor of Prognosis on Outcomes in Patients Undergoing Transarterial Chemoembolization(TACE)for Hepatocellular Carcinoma
XIANG Qian,CHEN Li,FU Dan,XU Qing,YE Bin,CHEN Xia. Sarcopenia as a Predictor of Prognosis on Outcomes in Patients Undergoing Transarterial Chemoembolization(TACE)for Hepatocellular Carcinoma[J]. Modern Digestion & Intervention, 2021, 0(2): 202-207
Authors:XIANG Qian  CHEN Li  FU Dan  XU Qing  YE Bin  CHEN Xia
Affiliation:(Department of Gastroenterology,the Sixth People's Hospital of Chengdu,Chengdu,Sichuan 610051,P.R.China;Radiology Department,the Sixth Peoplef s Hospital of Chengdu,Chengdu,Sichuan 610051,P.R.China;Oncology Department,the Sixth People's Hospital of Chengdu,Chengdu,Sichuan 610051,P.R.China)
Abstract:Objective The impact of sarcopenia on outcomes of patients undergoing Transarterial Chemoembolization(TACE)remains unclear.The purpose of this study was to evaluate the relationship between preoperative sarcopenia and prognosis on outcomes of TACE.Methods A total of 155 newly diagnosed patients who underwent TACE for hepatocellular carcinoma(HCC)between January 2014 and January 2018 at the Sixth People’s Hospital of Chengdu were enrolled.Data from 98 of the patients were retrospectively analyzed according to inclusion and exclusion criteria.Skeletal muscle index at L3 were evaluated by preoperative computed tomography images to define sarcopenia.Cumulative Time to Progress(TTP)and Overall Survive(OS)rates were calculated using Kaplan-Meier methods,and differences between curves of groups(sarcopenia,n=60;non-sarcopenia,n=38)were evaluated using the log-rank test.Prognostic significance was assessed with univariate and multivariate analyses,using Cox proportional hazards models.Results 95.92%(n=94)of tumor to progress and 88.78%(n=87)of death were observed during the study period[Median 11.0(7.85,14.8)months].The TTP(P<0.0001)and OS(P<0.0001)in HCC patients with sarcopenia were significantly worse than that in HCC patients without sarcopenia.Multivariate analysis identified the presence of sarcopenia(HR,2.265;95%CI,1.350~3.800,P=0.002),Barcelona Clinic Liver Cancer(BCLC)stage≥C(HR,1.627;95%CI,1.044~2.534,P=0.031),Eastern Cooperative Oncology Group performance status(ECOG-PS)≥2(HR,1.811;95%CI,1.050~3.125,P=0.033),and serum alpha-fetoprotein(AFP)>400μg/L(HR,1.867;95%CI,1.198~2.911,P=0.006)as independent predictors of poor OS.Conclusions 61.22%of HCC patients were associated with sarcopenia before the first time they underwent TACE.Sarcopenia was an independent risk factor for poor OS and could be recognized as an independent prognostic factor in patients with HCC treated with TACE.
Keywords:Sarcopenia  Transarterial Chemoembolization  Hepatocellular Carcinoma  Prognosis
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号